EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

What Was Tested

Researchers studied Octreotide and Somatostatin in this randomized controlled trial publication.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

The proportions of patients experiencing treatment success was a supportive analysis.

How the Study Was Run

The researchers set it up as a randomized, double-blind, open-label and placebo-controlled study.

Because people in this Octreotide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Octreotide.

Being open-label, the Octreotide study did not mask who received what.

Some participants received a placebo instead of Octreotide, giving a reference point.

This was a 16-week, randomized, double-blind, phase 3 trial (Clinicaltrials.gov: NCT00774930).

The primary endpoint was the percentage of days in which short-acting octreotide was used, which was assessed from daily diaries using an analysis of covariance including the stratification variables baseline short-acting octreotide use and frequency of diarrhea/flushing.

Adverse events were recorded at all visits.

What Was Measured

The subject headings attached to it are Antineoplastic Agents, Carcinoid Tumor, Drug Compounding, Gels, Malignant Carcinoid Syndrome, Neuroendocrine Tumors and Octreotide.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Octreotide and Somatostatin.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2016 (Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists), a journal based in United States.

More context: the Octreotide compound page and the Somatostatin compound page.